白蛋白结合型紫杉醇联合卡瑞利珠单抗治疗肺鳞癌的疗效分析  

Effect Analysis of Albumin-binding Paclitaxel Combined with Camreli⁃zumab in the Treatment of Lung Squamous Cell Carcinoma

作　　者：陈雷 陆锡燕 靳晓伟 周雷 马赛楠 CHEN Lei;LU Xiyan;JIN Xiaowei;ZHOU Lei;MA Sainan(Department of Oncology,Suqian Hospital of Nanjing Gulou Hospital Group(Suqian Hospital Affiliated to XuzhouMedical University),Suqian,Jiangsu Province,223800 China)

机构地区：[1]南京鼓楼医院集团宿迁医院(徐州医科大学附属宿迁医院)肿瘤科,江苏宿迁223800

出　　处：《中外医疗》2022年第32期172-175,共4页China & Foreign Medical Treatment

基　　金：宿迁市科技局2019年度市级指导性科技计划项目(Z2019156)。

摘　　要：目的 分析肺鳞癌患者采取白蛋白结合型紫杉醇、卡瑞利珠单抗联合方案治疗的应用效果与价值。方法 方便选取2020年1月—2021年9月南京鼓楼医院集团宿迁医院收治的82例Ⅲ/Ⅳ期肺鳞癌患者,根据随机抽签结果分为观察组(42例)与对照组(40例),对照组采用白蛋白结合型紫杉醇治疗,观察组采用白蛋白结合型紫杉醇联合卡瑞利珠单抗治疗。观察对比两组治疗效果,记录统计两组治疗后不良反应发生率;对患者进行为期1年的跟踪随访,统计两组无进展生存期及1年生存率。结果 观察组治疗有效率(52.38%)、疾病控制率(90.48%)均略高于对照组,差异无统计学意义(χ^(2)=0.447、0.574,P>0.05)。观察组患者不良反应(胃肠道反应、骨髓抑制、局部反应)总发生率(4.76%)低于对照组,差异有统计学意义(χ^(2)=7.940,P<0.05)。观察组患者无进展生存期长于对照组,且1年生存率高于对照组,差异有统计学意义(P<0.05)。结论 肺鳞癌患者通过采取白蛋白结合型紫杉醇联合卡瑞利珠单抗方案治疗具有确切疗效,同时安全性理想,减少不良反应。Objective To analyze the efficacy and value of albumin-binding paclitaxel and Camrelizumab combined therapy in patients with lung squamous cell carcinoma.Methods Conveniently selected 82 patients with stageⅢ/Ⅳlung squamous cell carcinoma admitted to Suqian Hospital of Nanjing Gulou Hospital Group from January 2020 to September 2021,and they were randomly divided into the observation group(42 cases)and the control group(40 cases)according to the results of the random draw.The control group was treated with albumin-binding paclitaxel,and the observation group was treated with albumin-binding paclitaxel combined with karelizumab.Observed and compared the treatment effect of the two groups,and recorded and counted the incidence of adverse reactions after treatment of the two groups;the patients were followed up for one year,and the progression-free survival period and one-year survival rate were counted.Results The treatment effective rate of 52.38%and disease control rate of 90.48%in the observation group were slightly higher than those in the control group,and the difference was not statis⁃tically significant(χ^(2)=0.447,0.574,P>0.05).The total incidence of adverse reactions(gastrointestinal reactions,my⁃elosuppression,and local reactions)in observation group was 4.76%,which was lower than that in control group,and the difference was statistically significant(χ^(2)=7.940,P<0.05).The progression-free survival time of the observation group was longer than that of the control group,and the 1-year survival rate was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion The combination of albumin-binding paclitaxel and carrellizumab in the treatment of patients with lung squamous cell carcinoma has exact efficacy,ideal safety and re⁃duced adverse reactions.

关 键 词：白蛋白结合型紫杉醇 卡瑞利珠单抗 肺鳞癌 疗效 

分 类 号：R730[医药卫生—肿瘤]